Antibody response to a non-conserved C-terminal part of human histone deacetylase 3 in colon cancer patients

International Journal of Cancer

Volumn 117, Issue 5, 2005, Pages 800-806

  Shebzukhov, Yuriy V ^a,b   Koroleva, Ekaterina P ^c   Khlgatian, Svetlana V ^b   Belousov, Pavel V ^b   Kuz'Mina, Ksenia E ^b   Radko, Boris V ^b   Longpre, Fanny ^b   Lagarkeva, Maria A ^b   Kadachigova, Tatiana S ^b   Gurova, Olga V ^d   Meshcheryakov, Andrey A ^e   Lichinitser, Mikhail R ^e   Knuth, Alexander ^f   Jager, Elke ^g   Kuprash, Dmitry V ^c   Nedospasov, Sergei A ^a,c  

^a SAIC FREDERICK INC   (United States)

^b MOSCOW STATE UNIVERSITY   (Russian Federation)

^c ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^d Municipal Clinical Hospital   (Russian Federation)

^e N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g KRANKENHAUS NORDWEST   (Germany)

Author keywords

Antibodies; Epitopes; HDAC3; Serology

Indexed keywords

COMPLEMENTARY DNA; EPITOPE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; RNA; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; BREAST CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC VALUE; DNA SEQUENCE; ENZYME ACTIVITY; GENE EXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; KIDNEY CANCER; MAJOR CLINICAL STUDY; MELANOMA; NORTHERN BLOTTING; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROLOGY; SERUM;

AMINO ACID SEQUENCE; ANTIBODIES, NEOPLASM; B-LYMPHOCYTES; BASE SEQUENCE; BLOTTING, WESTERN; COLONIC NEOPLASMS; DNA PRIMERS; EPITOPES; HISTONE DEACETYLASES; HUMANS; MOLECULAR SEQUENCE DATA; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 24344497186     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21240     Document Type: Article

References (29)

1. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995;92:11810-3.
2. Preuss KD, Zwick C, Bormann C, Neumann F, Pfreundschuh M. Analysis of the B-cell repertoire against antigens expressed by human neoplasms. Immunol Rev 2002;188:43-50.
3. Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2000;184:1-16.
4. Archer SY, Hodin RA. Histone acetylation and cancer. Curr Opin Genet Dev 1999;9:171-4.
5. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, Herman JG, Baylin SB. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002;31:141-9.
6. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, Moon EJ, Kim HS, Lee SK, Chung HY, Kim CW, Kim KW. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001;7:437-43.
7. Juan LJ, Shia WJ, Chen MH, Yang WM, Seto E, Lin YS, Wu CW. Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem 2000;275:20436-43.
8. Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E, Yao TP. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 2002;21:6236-45.
9. Kawai H, Li H, Avraham S, Jiang S, Avraham HK. Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. Int J Cancer 2003;107:353-8.
10. Glaser KB, Li J, Staver MJ, Wei RQ, Albert DH, Davidsen SK. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 2003;310:529-36.
11. Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ, Kim DY. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 2001;92:1300-4.
12. Patra SK, Patra A, Dahiya R. Histone deacetylase and DNA methyl-transferase in human prostate cancer. Biochem Biophys Res Commun 2001;287:705-13.
13. Toh Y, Yamamoto M, Endo K, Ikeda Y, Baba H, Kohnoe S, Yonemasu H, Hachitanda Y, Okamura T, Sugimachi K. Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma. Oncol Rep 2003;10:333-8.
14. Lagarkova MA, Koroleva EP, Kuprash DV, Boitchenko VE, Kashkarova UA, Nedospasov SA, Shebzukhov YV. Evaluation of humoral response to tumor antigens using recombinant expression-based serological mini-arrays (SMARTA). Immunol Lett 2003;85:71-4.
15. Scanlan MJ, Chen YT, Williamson B, Gure AO, Stockert E, Gordan JD, Tureci O, Sahin U, Pfreundschuh M, Old LJ. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 1998;76:652-8.
16. Scanlan MJ, Welt S, Gordon CM, Chen YT, Gure AO, Stockert E, Jungbluth AA, Ritter G, Jager D, Jager E, Knuth A, Old LJ. Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res 2002;62:4041-7.
17. Lagarkova MA, Boitchenko VE, Mescheryakov AA, Kashkarova UA, Nedospasov SA. Human cortactin as putative cancer antigen. Oncogene 2000;19:5204-7.
18. Kuimov AN, Kuprash DV, Petrov VN, Vdovichenko KK, Scanlan MJ, Jongeneel CV, Lagarkova MA, Nedospasov SA. Cloning and characterization of TNKL, a member of tankyrase gene family. Genes Immun 2001;2:52-5.
19. Koroleva EP, Lagarkova MA, Mesheryakov AA, Scanlan MJ, Old LJ, Nedospasov SA, Kuprash DV. Serological identification of antigens associated with renal cell carcinoma. Russ J Immunol 2002;7:229-38.
20. Koroleva EP, Lagar'kova MA, Khlgatian SV, Shebzukhov Y, Meshcheriakov AA, Lichinitser MR, Nedospasov SA, Kuprash DV. Serological study of a repertoire of human cancer antigens and autoantigens. Mol Biol (Mosk) 2004;38:233-8.
21. Archer SY, Meng S, Shei A, Hodin RA. p21 (WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 1998;95:6791-6.
22. Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202.
23. Keen JC, Yan L, Mack KM, Pettit C, Smith D, Sharma D, Davidson NE. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine. Breast Cancer Res Treat 2003;81:177-86.
24. Atadja P, Gao L, Kwon P, Trogani N, Walker H, Hsu M, Yeleswarapu L, Chandramouli N, Perez L, Versace R, Wu A, Sambucetti L, et al. Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res 2004;64:689-95.
25. Takami Y and Nakayama T. N-terminal region, C-terminal region, nuclear export signal, and deacetylation activity of histone deacetylase-3 are essential for the viability of the DT40 chicken B cell line. J Biol Chem 2000;275:16191-201.
26. Yang WM, Tsai SC, Wen YD, Fejer G, Seto E. Functional domains of histone deacetylase-3. J Biol Chem 2002;277:9447-54.
27. Khochbin S, Verdel A, Lemercier C, Seigneurin-Berny D. Functional significance of histone deacetylase diversity. Curr Opin Genet Dev 2001;11:162-6.
28. Zhang X, Wharton W, Yuan Z, Tsai SC, Olashaw N, Seto E. Activation of the growth-differentiation factor 11 gene by the histone deacetylase (HDAC) inhibitor trichostatin A and repression by HDAC3. Mol Cell Biol 2004;24:5106-18.
29. Huang BH, Laban M, Leung CH, Lee L, Lee CK, Salto-Tellez M, Raju GC, Hooi SC. Inhibition of histone deacetylase 2 increases apoptosis and p21(Cip1/WAF1) expression, independent of histone deacetylase 1. Cell Death Differ 2005;12:395-404.